“Zinc finger” gene therapy

Scientists at the Massachusetts General Hospital are exploring how the toxic clumps of proteins in the brain, which are seen as key players in the cognitive decline associated with Alzheimer’s, might be targeted via gene therapy. The researchers were able to introduce the gene therapy which uses proteins known as “zinc finger” protein transcription factors to alter the expression of certain genes or silence the gene expression that codes the toxic clumps. Read the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org